Markets:

Overview

News

Currencies

International

Treasuries

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

3.790 -0.100 (-2.57%)

Streaming Delayed Price Updated: 10:10 AM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Rocket Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 18, 2025

Via Benzinga

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) Posts Narrower Q3 2025 Loss, Advances Gene Therapy Pipeline ↗

November 06, 2025

Rocket Pharma posts a narrower-than-expected Q3 2025 loss. Key gene therapy pipeline advances include an FDA-accepted BLA for KRESLADI™ and a lifted clinical hold for its Danon Disease program.

Via Chartmill

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗

November 04, 2025

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.

Via Benzinga

FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock ↗

October 14, 2025

FDA accepts Rocket Pharmaceuticals' resubmission for Kresladi gene therapy in severe LAD-I, with a decision expected by March 2026.

Via Benzinga

These Analysts Slash Their Forecasts On Rocket Pharmaceuticals ↗

May 28, 2025

Via Benzinga

Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday ↗

October 14, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 14, 2025

Via Benzinga

Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy ↗

October 03, 2025

The company said that the decision is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of Fanskya.

Via Stocktwits

FDA Outlines Process To Speed Up Rare Disease Therapy Approvals ↗

September 04, 2025

FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.

Via Benzinga

Coty, Bilibili, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

August 21, 2025

Via Benzinga

Why Nordson Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket ↗

August 21, 2025

Via Benzinga

Which stocks are experiencing notable movement on Wednesday? ↗

August 20, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients ↗

August 20, 2025

The firm said that the FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys.

Via Stocktwits

Topics Death

Traders are paying attention to the gapping stocks in Wednesday's session. ↗

August 20, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.

Via Chartmill

TJX Posts Better-Than-Expected Earnings, Joins Rocket Pharmaceuticals, Guess? And Other Big Stocks Moving Higher On Wednesday ↗

August 20, 2025

Via Benzinga

FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy ↗

August 20, 2025

Rocket Pharmaceuticals shares rise after FDA clears its pivotal RP-A501 trial for Danon disease with adjusted dosing and updated treatment protocol.

Via Benzinga

Wednesday's pre-market session: top gainers and losers ↗

August 20, 2025

As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 20, 2025

Via Benzinga

Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket ↗

August 20, 2025

Via Benzinga

Why Is Rocket Pharma Stock Up 15% Pre-Market Today? ↗

August 20, 2025

The U.S. Food and Drug Administration has lifted the clinical hold on the company’s mid-stage study of RP-A501 for the treatment of Danon disease.

Via Stocktwits

Rocket (RCKT) Q2 Loss Narrows 16% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? ↗

July 30, 2025

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

Via Benzinga

Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours ↗

July 25, 2025

Rocket Pharmaceuticals downgraded by BofA after FDA halts Danon disease trial; company pivots toward earlier-stage gene therapy programs.

Via Benzinga

What's going on in today's pre-market session ↗

July 17, 2025

Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 17, 2025

Via Benzinga

Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May ↗

May 31, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty ↗

May 28, 2025

Rocket Pharmaceuticals faces trial delays, multiple downgrades, and reduced success expectations following RP-A501 safety concerns.

Via Benzinga

Booz Allen, FreshPet, Rocket Pharma Downgraded, While Vail Resorts And FICO Get An Upgrade – Top Wall Street Analyst Calls Today ↗

May 28, 2025

State Street received an upgrade from Truist, raising the stock to ‘Buy’ from ‘Hold’ and increasing its price target to $112 from $85.

Via Stocktwits

Topics ETFs Stocks

Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

May 28, 2025

Via Benzinga

This Informatica Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday ↗

May 28, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.